109 related articles for article (PubMed ID: 25381930)
1. HEK293-based production platform for γ-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA.
Hennig K; Raasch L; Kolbe C; Weidner S; Leisegang M; Uckert W; Titeux M; Hovnanian A; Kuehlcke K; Loew R
Hum Gene Ther Clin Dev; 2014 Dec; 25(4):218-28. PubMed ID: 25381930
[TBL] [Abstract][Full Text] [Related]
2. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
[TBL] [Abstract][Full Text] [Related]
3. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration.
Loew R; Meyer Y; Kuehlcke K; Gama-Norton L; Wirth D; Hauser H; Stein S; Grez M; Thornhill S; Thrasher A; Baum C; Schambach A
Gene Ther; 2010 Feb; 17(2):272-80. PubMed ID: 19865181
[TBL] [Abstract][Full Text] [Related]
4. Integrated strategy for the production of therapeutic retroviral vectors.
Carrondo M; Panet A; Wirth D; Coroadinha AS; Cruz P; Falk H; Schucht R; Dupont F; Geny-Fiamma C; Merten OW; Hauser H
Hum Gene Ther; 2011 Mar; 22(3):370-9. PubMed ID: 21043806
[TBL] [Abstract][Full Text] [Related]
5. SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa.
Titeux M; Pendaries V; Zanta-Boussif MA; Décha A; Pironon N; Tonasso L; Mejia JE; Brice A; Danos O; Hovnanian A
Mol Ther; 2010 Aug; 18(8):1509-18. PubMed ID: 20485266
[TBL] [Abstract][Full Text] [Related]
6. Disclosing the Parameters Leading to High Productivity of Retroviral Producer Cells Lines: Evaluating Random Versus Targeted Integration.
Bandeira VS; Tomás HA; Alici E; Carrondo MJ; Coroadinha AS
Hum Gene Ther Methods; 2017 Apr; 28(2):78-90. PubMed ID: 28301970
[TBL] [Abstract][Full Text] [Related]
7. Generation of High-Titer Self-Inactivated γ-Retroviral Vector Producer Cells.
Ghani K; Boivin-Welch M; Roy S; Dakiw-Piaceski A; Barbier M; Pope E; Germain L; Caruso M
Mol Ther Methods Clin Dev; 2019 Sep; 14():90-99. PubMed ID: 31312667
[TBL] [Abstract][Full Text] [Related]
8. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.
Schambach A; Mueller D; Galla M; Verstegen MM; Wagemaker G; Loew R; Baum C; Bohne J
Gene Ther; 2006 Nov; 13(21):1524-33. PubMed ID: 16763662
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector (GENEGRAFT).
Hum Gene Ther Clin Dev; 2014 Jun; 25(2):65-6. PubMed ID: 24933565
[No Abstract] [Full Text] [Related]
10. Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.
Feldman SA; Xu H; Black MA; Park TS; Robbins PF; Kochenderfer JN; Morgan RA; Rosenberg SA
Hum Gene Ther Methods; 2014 Aug; 25(4):253-60. PubMed ID: 25072603
[TBL] [Abstract][Full Text] [Related]
11. Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa.
Goto M; Sawamura D; Ito K; Abe M; Nishie W; Sakai K; Shibaki A; Akiyama M; Shimizu H
J Invest Dermatol; 2006 Apr; 126(4):766-72. PubMed ID: 16439972
[TBL] [Abstract][Full Text] [Related]
12. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange.
Coroadinha AS; Schucht R; Gama-Norton L; Wirth D; Hauser H; Carrondo MJ
J Biotechnol; 2006 Jul; 124(2):457-68. PubMed ID: 16529836
[TBL] [Abstract][Full Text] [Related]
13. Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene.
Loew R; Selevsek N; Fehse B; von Laer D; Baum C; Fauser A; Kuehlcke K
Mol Ther; 2004 May; 9(5):738-46. PubMed ID: 15120335
[TBL] [Abstract][Full Text] [Related]
14. Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope.
Mirow M; Schwarze LI; Fehse B; Riecken K
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452336
[TBL] [Abstract][Full Text] [Related]
15. Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral LTR vector.
Cornils K; Bartholomae CC; Thielecke L; Lange C; Arens A; Glauche I; Mock U; Riecken K; Gerdes S; von Kalle C; Schmidt M; Roeder I; Fehse B
Exp Hematol; 2013 Jan; 41(1):28-38.e3. PubMed ID: 22989760
[TBL] [Abstract][Full Text] [Related]
16. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
17. Reliable generation of stable high titer producer cell lines for gene therapy.
Rattmann I; Kleff V; Feldmann A; Ludwig C; Sorg UR; Opalka B; Moritz T; Flasshove M
Intervirology; 2007; 50(3):197-203. PubMed ID: 17283445
[TBL] [Abstract][Full Text] [Related]
18. Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Baum C; Thrasher AJ; Williams DA; Nordling DL; Reeves L; Malik P
Gene Ther; 2012 Mar; 19(3):246-54. PubMed ID: 21753795
[TBL] [Abstract][Full Text] [Related]
19. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
20. Self-inactivating retroviral vectors with improved RNA processing.
Kraunus J; Schaumann DH; Meyer J; Modlich U; Fehse B; Brandenburg G; von Laer D; Klump H; Schambach A; Bohne J; Baum C
Gene Ther; 2004 Nov; 11(21):1568-78. PubMed ID: 15372067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
